Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aubagio
Special Reports
The top 10 drug patent expirations of 2023
The Fierce Pharma team didn't want AbbVie's Humira to have the entire patent-cliff spotlight this year, so we're presenting this special report on that drug and nine others.
Fraiser Kansteiner
,
Eric Sagonowsky
,
Zoey Becker
,
Kevin Dunleavy
,
Angus Liu
Mar 13, 2023 3:00am
TG Therapeutics wins green light for MS antibody Briumvi
Dec 29, 2022 9:46am
Novartis sues FDA, claiming Sanofi's Aubagio isn't really new
Mar 11, 2021 11:34am
FDA hits Novartis with unexpected delay on MS drug
Jun 3, 2020 11:55am
Novartis' leukemia drug tops Sanofi's Aubagio in MS study
May 27, 2020 10:10am
Which new MS drug do doctors like best? You might be surprised
Nov 19, 2019 11:16am
